You are here

  • Home
  • Archive
  • Volume 40, Issue 6
  • Possible founder effect of rapsyn N88K mutation and identification of novel rapsyn mutations in congenital myasthenic syndromes

Article Text

Article menu
Download PDFPDF
Online mutation report
Possible founder effect of rapsyn N88K mutation and identification of novel rapsyn mutations in congenital myasthenic syndromes
  1. P Richard1,*,
  2. K Gaudon1,2,
  3. F Andreux3,*,
  4. E Yasaki2,
  5. C Prioleau2,
  6. S Bauché2,
  7. A Barois4,*,
  8. C Ioos2,*,
  9. M Mayer5,*,
  10. M C Routon5,*,
  11. M Mokhtari6,*,
  12. J P Leroy2,7,
  13. E Fournier8,*,
  14. B Hainque2,*,
  15. J Koenig2,
  16. M Fardeau2,
  17. B Eymard2,*,
  18. D Hantaï2
  1. 1Unité Fonctionnelle de Cardiogénétique et Myogénétique, Service de Biochimie B & IFR 14, Hôpital de la Salpêtriére, Paris, France
  2. 2INSERM U.582, Institut de Myologie & IFR 14, Hôpital de la Salpêtriére, Paris, France
  3. 3Fédération de Neurologie Mazarin & IFR des Neurosciences, Hôpital de la Salpêtriére, Paris, France
  4. 4Service de Neuropédiatrie, Hôpital Raymond Poincaré, Garches, France
  5. 5Service de Neuropédiatrie, Hôpital Saint Vincent de Paul, Paris, France
  6. 6Service de Médecine Néonatale, Hôpital Saint Vincent de Paul, Paris, France
  7. 7Centre Hospitalier Universitaire, Brest, France
  8. 8Service d'Electrophysiologie & IFR des Neurosciences, Hôpital de la Salpêtriére, Paris, France
  1. Correspondence to:
 Dr D Hantaï, INSERM U.582, Institut de Myologie, Hôpital de la Salpêtriére, 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France;
 d.hantai{at}myologie.chups.jussieu.fr

https://doi.org/10.1136/jmg.40.6.e81

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Congenital myasthenic syndromes (CMS) constitute a group of rare diseases heterogeneous both in terms of their mode of hereditary transmission (recessive and dominant forms) and their pathophysiology (with presynaptic, synaptic, and postsynaptic defects). They are responsible for dysfunction of neuromuscular transmission giving rise to a condition of muscle weakness which is accentuated by exertion. In most cases, CMS begin in early childhood but later onset in adulthood is possible. Severity also varies from severe with respiratory failure to mild expression.1,2

    The majority of CMS primarily affect postsynaptic function and are the result of mutations located in the muscle acetylcholine receptor (AChR) subunit genes that lead to kinetic abnormalities or to AChR deficiency. For example, an increased response occurs in the slow channel syndromes associated with dominant mutations in AChR subunits delaying channel closure or increasing the affinity of the receptor for acetylcholine. However, the most commonly encountered CMS is a deficiency in AChR which occurs with recessive mutations. Most of these mutations are located in the AChR ε subunit.3,4

    Recent advances have shown that mutations in rapsyn are also involved in recessive forms of postsynaptic CMS and cause AChR deficiency.5 Rapsyn is a 43 kDa postsynaptic protein involved in development and maintenance of the molecular architecture of the postsynaptic membrane by participating in the clustering of AChR after binding of neural agrin to its muscle specific receptor tyrosine kinase, MuSK.6,7 The rapsyn gene (RAPSN) has been mapped to chromosome 11p11.2 p11.1 and comprises eight exons.8 The primary structure of rapsyn is predicted to contain several functional domains such as an N-terminus myristoylation signal, seven tetratricopeptide repeats (residues 6-279), a coiled-coiled domain (298-331), a cysteine rich RING-H2 domain (363-402), and a serine phosphorylation site at codon 406.9,10

    The aim of this …

    View Full Text